Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan

被引：1

作者：

Yang, Chun-Chi ^{[1
]}

Huang, Chung-Feng ^{[2
,3
,4
]}

Chang, Te-Sheng ^{[5
,6
]}

Lo, Ching-Chu ^{[7
]}

Hung, Chao-Hung ^{[8
]}

Huang, Chien-Wei ^{[9
]}

Chong, Lee-Won ^{[10
,11
]}

Cheng, Pin-Nan ^{[12
,13
]}

Yeh, Ming-Lun ^{[2
,3
,14
]}

Peng, Cheng-Yuan ^{[15
,16
]}

Cheng, Chien-Yu ^{[17
]}

Huang, Jee-Fu ^{[2
,3
,14
,18
,19
,20
]}

Bair, Ming-Jong ^{[21
,22
]}

Lin, Chih-Lang ^{[23
,24
]}

Yang, Chi-Chieh ^{[25
]}

Wang, Szu-Jen ^{[26
]}

Hsieh, Tsai-Yuan ^{[27
]}

Lee, Tzong-Hsi ^{[28
]}

Lee, Pei-Lun ^{[29
]}

Wu, Wen-Chih ^{[30
]}

Lin, Chih-Lin ^{[31
]}

Su, Wei-Wen ^{[32
]}

Yang, Sheng-Shun ^{[33
]}

Wang, Chia-Chi ^{[34
,35
]}

Hu, Jui-Ting ^{[36
]}

Mo, Lein-Ray ^{[37
]}

Chen, Chun-Ting ^{[27
,38
]}

Huang, Yi-Hsiang ^{[39
,40
,41
]}

Chang, Chun-Chao ^{[42
,43
]}

Huang, Chia-Sheng ^{[44
]}

Chen, Guei-Ying ^{[45
]}

Kao, Chien-Neng ^{[46
]}

Tai, Chi-Ming ^{[47
,48
]}

Liu, Chun-Jen ^{[49
]}

Lee, Mei-Hsuan ^{[50
]}

Kuo, Hsing-Tao ^{[1
]}

Tsai, Pei-Chien ^{[2
,3
,14
]}

Dai, Chia-Yen ^{[2
,3
,14
]}

Kao, Jia-Horng ^{[49
]}

Lin, Han-Chieh ^{[39
,40
,41
]}

Chuang, Wang-Long ^{[2
,3
]}

Tseng, Kuo-Chih ^{[51
,52
]}

Chen, Chi-Yi ^{[53
]}

Yu, Ming-Lung ^{[2
,3
,8
,14
,18
,19
,20
]}

机构：

[1] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, 100,Tzyou 1st Rd, Kaohsiung, Taiwan

[3] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatitis Ctr, 100,Tzyou 1st Rd, Kaohsiung, Taiwan

[4] Kaohsiung Med Univ, Coll Med, PhD Program Translat Med, Acad Sinica, Kaohsiung, Taiwan

[5] ChiaYi Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Chiayi, Taiwan

[6] Chang Gung Univ, Coll Med, Taoyuan, Taiwan

[7] St Martin De Porres Hosp, Dept Internal Med, Div Gastroenterol, Chiayi, Taiwan

[8] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan

[9] Kaohsiung Armed Forces Gen Hosp, Dept Gastroenterol, Kaohsiung, Taiwan

[10] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan

[11] Shin Kong Wu Ho Su Mem Hosp, Dept Internal Med, Div Hepatol & Gastroenterol, Taipei, Taiwan

[12] Natl Cheng Kung Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[13] Natl Cheng Kung Univ, Coll Med, Tainan, Taiwan

[14] Kaohsiung Med Univ, Hepatitis Res Ctr, Coll Med, Ctr Liquid Biopsy & Cohort Res, Kaohsiung, Taiwan

[15] China Med Univ Hosp, Ctr Digest Med, Dept Internal Med, Taichung, Taiwan

[16] China Med Univ, Sch Med, Taichung, Taiwan

[17] Taoyuan Gen Hosp, Div Infect Dis, Dept Internal Med, Minist Hlth & Welf, Taoyuan, Taiwan

[18] Natl Sun Yat Sen Univ, Sch Med, Kaohsiung, Taiwan

[19] Natl Sun Yat Sen Univ, Coll Med, Doctoral Program Clin & Expt Med, Kaohsiung, Taiwan

[20] Natl Sun Yat Sen Univ, Ctr Excellence Metab Associated Fatty Liver Dis, Kaohsiung, Taiwan

[21] Taitung Mackay Mem Hosp, Dept Internal Med, Div Gastroenterol, Taitung, Taiwan

[22] Mackay Med Coll, New Taipei City, Taiwan

[23] Chang Gung Univ, Liver Res Unit, Dept Hepatogastroenterol, Chang Gung Mem Hosp Keelung,Coll Med, Keelung, Taiwan

[24] Chang Gung Univ, Chang Gung Mem Hosp Keelung, Coll Med, Community Med Res Ctr, Keelung, Taiwan

[25] Show Chwan Mem Hosp, Dept Gastroenterol, Div Internal Med, Changhua, Taiwan

[26] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[27] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[28] Far Eastern Mem Hosp, Div Gastroenterol, New Taipei City, Taiwan

[29] Chi Mei Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Tainan, Taiwan

[30] Wen Chih Wu Clin, Kaohsiung, Taiwan

[31] Taipei City Hosp, Renai Branch, Dept Gastroenterol, Taipei, Taiwan

[32] Changhua Christian Hosp, Dept Gastroenterol & Hepatol, Changhua, Taiwan

[33] Taichung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taichung, Taiwan

[34] Tzu Chi Univ, Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Taipei, Taiwan

[35] Tzu Chi Univ, Taipei Tzu Chi Hosp, Sch Med, Taipei, Taiwan

[36] Cathay Gen Hosp, Liver Ctr, Taipei, Taiwan

[37] Tainan Municipal Hosp, Div Gastroenterol, Show Chwan Med Care Corp, Tainan, Taiwan

[38] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Gastroenterol,Penghu Branch, Taipei, Taiwan

[39] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[40] Taipei Vet Gen Hosp, Healthcare & Serv Ctr, Taipei, Taiwan

[41] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Coll Med, Taipei, Taiwan

[42] Taipei Med Univ Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Taipei, Taiwan

[43] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med,Div Gastroenterol & Hepatol, Taipei, Taiwan

[44] Yang Ming Hosp, Chiayi, Taiwan

[45] Penghu Hosp, Minist Hlth & Welf, Penghu, Taiwan

[46] Natl Taiwan Univ Hosp, Hsin Chu Branch, Hsinchu, Taiwan

[47] I Shou Univ, E Da Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Kaohsiung, Taiwan

[48] I Shou Univ, Coll Med, Sch Med Int Students, Kaohsiung, Taiwan

[49] Natl Taiwan Univ Hosp, Dept Internal Med, Hepatitis Res Ctr, Taipei, Taiwan

[50] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Taipei, Taiwan

来源：

INFECTIOUS DISEASES AND THERAPY | 2024年 / 13卷 / 06期

关键词：

Hepatitis C; Direct-acting antivirals; Glecaprevir; Pibrentasvir; Real world; Taiwan;

D O I：

10.1007/s40121-024-00968-5

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction Eight-week glecaprevir/pibrentasvir (GLE/PIB) is indicated for treatment-na & iuml;ve (TN) patients with chronic hepatitis C (CHC), with or without compensated cirrhosis. Given that the Taiwanese government is committed to eliminating hepatitis C virus (HCV) by 2025, this study aimed to measure real-world evidence for TN patients using 8-week GLE/PIB in the Taiwan HCV Registry (TACR).Methods The data of patients with CHC treated with 8-week GLE/PIB were retrieved from TACR, a nationwide registry program organized by the Taiwan Association for the Study of the Liver (TASL). Treatment efficacy, defined as a sustained virologic response at posttreatment week 12 (SVR12), was assessed in the modified intention-to-treat (mITT) population, which excluded patients who were lost to follow-up or lacked SVR12 data. The safety profile of the ITT population was assessed.Results A total of 7246 (6897 without cirrhosis; 349 with cirrhosis) patients received at least one dose of GLE/PIB (ITT), 7204 of whom had SVR12 data available (mITT). The overall SVR12 rate was 98.9% (7122/7204) among all patients, 98.9% (6780/6856) and 98.3% (342/348) among patients without and with cirrhosis, respectively. For the selected subgroups, which included patients with genotype 3 infection, diabetes, chronic kidney disease, people who injected drugs, and those with human immunodeficiency virus coinfection, the SVR12 rates were 95.1% (272/286), 98.9% (1084/1096), 99.0% (1171/1183), 97.4% (566/581), and 96.1% (248/258), respectively. Overall, 14.1% (1021/7246) of the patients experienced adverse events (AEs). Twenty-two patients (0.3%) experienced serious AEs, and 15 events (0.2%) resulted in permanent drug discontinuation. Only one event was considered treatment drug related.Conclusion Eight-week GLE/PIB therapy was effective and well tolerated in all TN patients, regardless of cirrhosis status.

引用

页码：1199 / 1213

页数：15

共 50 条

[1] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Te-Sheng Chang
Chung-Feng Huang
Hsing-Tao Kuo
Ching-Chu Lo
Chien-Wei Huang
Lee-Won Chong
Pin-Nan Cheng
Ming-Lun Yeh
Cheng-Yuan Peng
Chien-Yu Cheng
Jee-Fu Huang
Ming-Jong Bair
Chih-Lang Lin
Chi-Chieh Yang
Szu-Jen Wang
Tsai-Yuan Hsieh
Tzong-Hsi Lee
Pei-Lun Lee
Wen-Chih Wu
Chih-Lin Lin
Wei-Wen Su
Sheng-Shun Yang
Chia-Chi Wang
Jui-Ting Hu
Lein-Ray Mo
Chun-Ting Chen
Yi-Hsiang Huang
Chun-Chao Chang
Chia-Sheng Huang
Guei-Ying Chen
Chien-Neng Kao
Chi-Ming Tai
Chun-Jen Liu
Mei-Hsuan Lee
Pei-Chien Tsai
Chia-Yen Dai
Jia-Horng Kao
Han-Chieh Lin
Wang-Long Chuang
Chi-Yi Chen
Kuo-Chih Tseng
Chao-Hung Hung
Ming-Lung Yu
Hepatology International, 2023, 17 : 550 - 561
[2] Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
Nancy Reau
Wei-Han Cheng
Qiujun Shao
Steven E. Marx
Hannah Brooks
Anthony Martinez
Infectious Diseases and Therapy, 2023, 12 : 1849 - 1860
[3] Real-world effectiveness and safety of 8-week glecaprevir/pibrentasvir for treatment-naive patients from Taiwan nationwide HCV registry
Huang, Chung-Feng
Chang, Te-Sheng
Kuo, Hsing-Tao
Huang, Chien-Wei
Mo, Lien-Ray
Tai, Chi-Ming
Tseng, Kuo-Chih
Bair, Ming-Jong
Wang, Sih-Ren
Lo, Ching-Chu
Chong, Lee-Won
Cheng, Pin-Nan
Yeh, Ming-Lun
Peng, Cheng-Yuan
Cheng, Chien-Yu
Huang, Jee-Fu
Lin, Chih-Lang
Yang, Chi-Chieh
Hsieh, Tsai-Yuan
Lee, Tzong-Hsi
Lee, Pei-Lun
Wu, Wen-Chih
Lin, Chih-Lin
Su, Wei-Wen
Yang, Sheng-Shun
Wang, Chia-Chi
Hu, Jui-Ting
Chen, Chun-Ting
Huang, Yi-Hsiang
Chang, Chun-Chao
Huang, Chia-Sheng
Chen, Guei-Ying
Kao, Chien-Neng
Liu, Chun-Jen
Lee, Mei-Hsuan
Tsai, Pei-Chien
Dai, Chia-Yen
Kao, Jia-Horng
Lin, Han-Chieh
Chuang, Wan-Long
Hung, Chao-Hung
Chen, Chi-Yi
Yu, Ming-Lung
JOURNAL OF HEPATOLOGY, 2024, 80 : S832 - S833
[4] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
Chang, Te-Sheng
Huang, Chung-Feng
Kuo, Hsing-Tao
Lo, Ching-Chu
Huang, Chien-Wei
Chong, Lee-Won
Cheng, Pin-Nan
Yeh, Ming-Lun
Peng, Cheng-Yuan
Cheng, Chien-Yu
Huang, Jee-Fu
Bair, Ming-Jong
Lin, Chih-Lang
Yang, Chi-Chieh
Wang, Szu-Jen
Hsieh, Tsai-Yuan
Lee, Tzong-Hsi
Lee, Pei-Lun
Wu, Wen-Chih
Lin, Chih-Lin
Su, Wei-Wen
Yang, Sheng-Shun
Wang, Chia-Chi
Hu, Jui-Ting
Mo, Lein-Ray
Chen, Chun-Ting
Huang, Yi-Hsiang
Chang, Chun-Chao
Huang, Chia-Sheng
Chen, Guei-Ying
Kao, Chien-Neng
Tai, Chi-Ming
Liu, Chun-Jen
Lee, Mei-Hsuan
Tsai, Pei-Chien
Dai, Chia-Yen
Kao, Jia-Horng
Lin, Han-Chieh
Chuang, Wang-Long
Chen, Chi-Yi
Tseng, Kuo-Chih
Hung, Chao-Hung
Yu, Ming-Lung
HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 550 - 561
[5] Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
Advances in Therapy, 2020, 37 : 4033 - 4042
[6] Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment naive patients with compensated cirrhosis: real-world experience from Taiwan HCV registry
Hung, Chao-Hung
Chang, Te-Sheng
Huang, Chung-Feng
Kuo, Hsing-Tao
Lo, Ching-Chu
Huang, Chien-Wei
Chong, Lee-Won
Cheng, Pin-Nan
Yeh, Ming-Lun
Peng, Cheng-Yuan
Cheng, Chien-Yu
Huang, Jee-Fu
Bair, Ming-Jong
Lin, Chih-Lang
Yang, Chi-Chieh
Wang, Sih-Ren
Hsieh, Tsai-Yuan
Lee, Tzong-Hsi
Lee, Pei-Lun
Wu, Wen-Chih
Lin, Chih-Lin
Su, Wei-Wen
Yang, Shengshun
Wang, Chia-Chi
Hu, Jui-Ting
Mou, Lien-Juei
Chen, Chun-Ting
Huang, Yi-Hsiang
Chang, Chun-Chao
Huang, Jia-Sheng
Chen, Guei-Ying
Gao, Jian-Neng
Tai, Chi-Ming
Liu, Chun-Jen
Lee, Mei-Hsuan
Tsai, Pei-Chien
Dai, Chia-Yen
Kao, Jia-Horng
Lin, Han-Chieh
Chuang, Wan-Long
Chen, Chiyi
Tseng, Kuo-Chih
Yu, Ming-Lung
JOURNAL OF HEPATOLOGY, 2022, 77 : S595 - S596
[7] Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
Advances in Therapy, 2020, 37 : 4755 - 4756
[8] Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive, Compensated Cirrhotic HCV Patients
Reau, Nancy
Cheng, Wei-Han
Shao, Qiujun
Marx, Steven E.
Brooks, Hannah
Martinez, Anthony
INFECTIOUS DISEASES AND THERAPY, 2023, 12 (07) : 1849 - 1860
[9] Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis
Cornberg, Markus
Hueppe, Dietrich
Sarrazin, Christoph
Ahumada, Adriana
Plaza, Francisco Jorquera
Marino, Zoe
Otano, Juan Isidro Uriz
Conway, Brian
Myles, Lindsay
Ramji, Alnoor
Abergel, Armand
Asselah, Tarik
Larrey, Dominique
Aghemo, Alessio
Andreoni, Massimo
Gasbarrini, Antonio
Lampertico, Pietro
Persico, Marcello
Villa, Erica
Carmiel, Michal
Chodick, Gabriel
Weil, Clara
Bhagat, Abhi
Bondin, Mark
Butrymowicz, Isabel
Song, Yanna
Semizarov, Dimitri
Sonparote, Sadhana
Llamas, Cynthia
ADVANCES IN THERAPY, 2024, 41 (12) : 4669 - 4682
[10] Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
Steven L. Flamm
Jens Kort
Steven E. Marx
John Strezewski
Douglas E. Dylla
Bruce Bacon
Michael P. Curry
Naoky Tsai
Nicole Wick
Advances in Therapy, 2020, 37 : 2267 - 2274

← 1 2 3 4 5 →